17.45Open17.45Pre Close0 Volume222 Open Interest240.00Strike Price0.00Turnover46.54%IV5.13%PremiumDec 20, 2024Expiry Date4.89Intrinsic Value100Multiplier26DDays to Expiry12.56Extrinsic Value100Contract SizeAmericanOptions Type0.5984Delta0.0127Gamma16.27Leverage Ratio-0.2433Theta0.0942Rho9.74Eff Leverage0.2535Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet